Objective: To detect the aberrant expression of circulating miRNAs and explore thepotential early diagnostic biomarkers in patients with Parkinson’s disease (PD).

Background: In the past years, miRNAs were found to be present in bodyfluids including blood, plasma, serum, saliva, urine, and milk. Circulating miRNAs may serve as novel diagnostic and prognostic biomarkers for human diseases. miRNA expression profiles in PD-diagnosed patients have been analyzed and reported , and the function of miRNAs in regulating PD has been thoroughly discussed. Although there were a few studies examining the expression pattern of circulating miRNAs in the blood samples of PD-diagnosed patients, it is still unidentified for the PD-specific miRNAs that can be applied for clinical diagnosis and/or prognosis of PD.

Method: Plasma samples were collected from 25 treatment-naïve PD-diagnosed patients and 25 healthy controls followed by a real-time PCR-based miRNA screening analysis of neuron disease-related miRNAs.

Results: A subset of miRNAs with aberrant expression levels in the plasma of PD-diagnosed patients were identified including upregulation of miR-27aand downregulation of let-7a,let-7f,miR-142-3p,and miR-222 with the AUC values more than 0.8 derived from the receiver operating characteristic curves.

Conclusion: The high sensitivity and specificity of the circulating miRNAs may enable early diagnosis of PD. The study provides a group of novel miRNA candidates for detecting PD.

« Back to 2019 International Congress

MDS Abstracts - https://www.mdsabstracts.org/abstract/identification-of-aberrant-circulating-mirnas-in-parkinsons-disease-plasma-samples/